Early stage pancreatic cancer is typically asymptomatic, making it difficult to detect before it advances and becomes hard to treat. Johns Hopkins University scientists have developed a novel approach by combining a liquid biopsy based on circulating tumor DNA (ctDNA) with an analysis of four protein biomarkers to create the basis for a potential biomarker screening tool for the early identification of pancreatic cancer.